Arcturus Therapeutics Holdings Inc.
ARCT
$9.97
$0.343.53%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -3.68% | 29.06% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -3.68% | 29.06% | |||
| Cost of Revenue | -90.46% | -20.30% | |||
| Gross Profit | 553.15% | 73.77% | |||
| SG&A Expenses | -8.63% | -8.60% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.61% | -17.72% | |||
| Operating Income | 30.96% | 49.61% | |||
| Income Before Tax | 34.81% | 53.09% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 34.78% | 53.09% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 34.78% | 53.09% | |||
| EBIT | 30.96% | 49.61% | |||
| EBITDA | 32.37% | 50.81% | |||
| EPS Basic | 34.84% | 53.27% | |||
| Normalized Basic EPS | 34.85% | 53.29% | |||
| EPS Diluted | 34.84% | 53.36% | |||
| Normalized Diluted EPS | 34.85% | 53.29% | |||
| Average Basic Shares Outstanding | 0.08% | 0.40% | |||
| Average Diluted Shares Outstanding | 0.08% | 0.40% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||